Résumés
Résumé
Le bon fonctionnement de la cellule dépend du contrôle fin des mécanismes transcriptionnels et traductionnels. De nombreuses études ont établi que les dérèglements transcriptionnels peuvent être à l’origine de maladies telles que le cancer, l’obésité et le diabète. Depuis une décennie, le rôle de la traduction des ARNm dans certaines de ces pathologies et son contrôle par la voie PI3K/Akt/mTOR a été démontré. La rapamycine, inhibiteur spécifique de mTOR, présente une forte activité anti-proliférative dans plusieurs types de cancer. De récentes études démontrent qu’elle pourrait potentiellement être efficace dans le traitement de l’obésité et du diabète. La rapamycine et ses analogues semblent donc destinés à un avenir prometteur.
Summary
Gene regulation by transcriptional and post-translational mechanisms is implicated in the regulation of cellular homeostasis. Transcriptional deregulation has been largely documented in the etiology of diseases such as cancer, obesity and diabetes. During the past decade, the control of translation initiation by the PI3K/Akt/mTOR pathway in the development of these pathologies has been documented. Rapamycin, a specific inhibitor of mTOR, demonstrates considerable anti-proliferative activity against numerous cancer types. Recent studies also demonstrated that rapamycin may be beneficial in the treatment of obesity and diabetes. Rapamycin and its analogs seem destined for a promising future and will help in the development of novel therapeutic strategies.
Parties annexes
Références
- 1. Holland EC, Sonenberg N, Pandolfi PP, Thomas G. Signaling control of mRNA translation in cancer pathogenesis. Oncogene 2004 ; 23 : 3138-44.
- 2. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999 ; 68 : 913-63.
- 3. Mamane Y, Petroulakis E, Rong L, et al. eIF4E-from translation to transformation. Oncogene 2004 ; 23 : 3172-9.
- 4. Shi Y, Taylor SI, Tan SL, Sonenberg N. When translation meets metabolism: multiple links to diabetes. Endocrinol Rev 2003 ; 24 : 91-101.
- 5. Ruggero D, Montanaro L, Ma L, et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004 ; 10 : 484-6.
- 6. Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy.Nature 2004 ; 428 : 332-7.
- 7. Avdulov S, Li S, Michalek V, et al. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells.Cancer Cell 2004 ; 5 : 553-63.
- 8. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004 ; 18 : 1926-45.
- 9. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005 ; 37 : 19-24.
- 10. Richardson CJ, Schalm SS, Blenis J. PI3-kinase and TOR: PIKTORing cell growth. Semin Cell Dev Biol 2004 ; 15 : 147-59.
- 11. Proud CG. mTOR-mediated regulation of translation factors by amino acids. Biochem Biophys Res Commun 2004 ; 313 : 429-36.
- 12. Lynch M, Fitzgerald C, Johnston KA, et al. Activated eIF4E-binding protein slows G1 progression and blocks transformation by c-myc without inhibiting cell growth. J Biol Chem 2004 ; 279 : 3327-39.
- 13. Meyuhas O. Synthesis of the translational apparatus is regulated at the translational level. Eur J Biochem 2000 ; 267 : 6321-30.
- 14. Pende M, Um SH, Mieulet V. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal ethality and rapamycin-sensitive 5’-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway.Mol Cell Biol 2004 ; 24 : 3112-24.
- 15. Rao RD, Buckner JC, Sarkaria JN. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr Cancer Drug Targets 2004 ; 4 : 621-35.
- 16. Dutcher JP. Mammalian target of rapamycin (mTOR) inhibitors. Curr OncolRep 2004 ; 6 : 111-5.
- 17. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002 ; 110 : 163-75.
- 18. Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002 ; 110 : 177-89.
- 19. Kim DH, Sarbassov DD, Ali SM, et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. MolCell 2003 ; 11 : 895-904.
- 20. Sarbassov D, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.Curr Biol 2004 ; 14 : 1296-302.
- 21. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004 ; 6 : 1122-8.
- 22. Yonezawa K, Tokunaga C, Oshiro N, Yoshino K. Raptor, a binding partner of target of rapamycin. BiochemBiophys Res Commun 2004 ; 313 : 437-41.
- 23. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005 ; 307 : 1098-101.
- 24. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM. Transcriptional regulation of adipogenesis. Genes Dev 2000 ; 14 : 1293-307.
- 25. Bell A, Grunder L, Sorisky A. Rapamycin inhibits human adipocyte differentiation in primary culture. Obes Res 2000 ; 8 : 249-54.
- 26. Kim JE, Chen J. Regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 2004 ; 53 : 2748-56.
- 27. El-Chaar D, Gagnon A, Sorisky A. Inhibition of insulin signaling and adipogenesis by rapamycin : effect on phosphorylation of p70 S6 kinase versus eIF4E-BP1.Int J Obes Relat Metab Disord 2004 ; 28 : 191-8.
- 28. Tsukiyama-Kohara K, Poulin F, Kohara M, et al. Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1. Nat Med 2001 ; 7 : 1128-32.
- 29. Harrington LS, Findlay GM, Lamb RF. Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci 2005 ; 30 : 35-42.
- 30. Haruta T, Uno T, Kawahara J, et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol 2000 ; 14 : 783-94.
- 31. Zhang H, Cicchetti G, Onda H, et al. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 2003 ; 112 : 1223-33.
- 32. Khamzina L, Veilleux A, Bergeron S, Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology 2005 ; 146 : 1473-81.
- 33. Um SH, Frigerio F, Watanabe M, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004 ; 431 : 200-5.
- 34. Bouzakri K, Roques M, Gual P, et al. Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes. Diabetes 2003 ; 52 : 1319-25.